{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T03:18:37Z","timestamp":1781925517561,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>mRNA-based vaccines played a key role in fighting the global COVID-19 pandemic by saving millions of lives. In rare cases, however, the BNT162b2 vaccine has been associated with severe adverse reactions e.g. myocarditis (OE ratio 2.78; 95% CI 2.61; 2.95) [Faksova in Vaccine 42(9):2200-2211, 2024, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"10.1016\/j.vaccine.2024.01.100\" ext-link-type=\"doi\">https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.100<\/jats:ext-link>, Schwab in Clin Res Cardiol 112(3):431-440, 2022, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"10.1007\/s00392-022-02129-5\" ext-link-type=\"doi\">https:\/\/doi.org\/10.1007\/s00392-022-02129-5<\/jats:ext-link>]. Here, we describe the case of a 38-year-old man who developed a wide variety of long-term symptoms (fatigue, dizziness, palpitations with recurrent syncopes, paresthesia, paresis and fasciculations) following his first mRNA-based BNT162b2 COVID-19 vaccination. 143\u00a0days after vaccination, a subsequent COVID-19 infection was associated with exacerbation of paresis and a temporary loss of vision. After ruling out other causes and due to the immediate temporal association, an adverse reaction to vaccination appears likely. The fact that these symptoms worsened after a subsequent acute COVID 19 infection hints at the possibility of a common underlying pathophysiology. This case combines two clinical phenomena that have emerged during the COVID 19 pandemic, side effects associated with novel vaccines and Post-COVID Syndrome.<\/jats:p>","DOI":"10.1007\/s15010-024-02439-y","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T06:36:43Z","timestamp":1733121403000},"page":"741-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Syncopes, paresis and loss of vision after COVID-19 mRNA-based vaccination and SARS-CoV-2 infection"],"prefix":"10.1007","volume":"53","author":[{"given":"Tobias","family":"Weirauch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundolf","family":"Sch\u00fcttfort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J. G. T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"2439_CR1","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","volume":"42","author":"K Faksova","year":"2024","unstructured":"Faksova K, Walsh D, Jiang Y, Griffin J, Phillips A, Gentile A, Kwong JC, Macartney K, Naus M, Grange Z, Escolano S, Sepulveda G, Shetty A, Pillsbury A, Sullivan C, Naveed Z, Janjua NZ, Giglio N, Per\u00e4l\u00e4 J, Nasreen S, Gidding H, Hovi P, Vo T, Cui F, Deng L, Cullen L, Artama M, Lu H, Clothier HJ, Batty K, Paynter J, Petousis-Harris H, Buttery J, Black S, Hviid A. COVID-19 vaccines and adverse events of special interest: a multinational global vaccine data network (GVDN) cohort study of 99 million vaccinated individuals. Vaccine. 2024;42:2200\u201311. https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.100. (Epub 2024 Feb 12 PMID: 38350768).","journal-title":"Vaccine"},{"key":"2439_CR2","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00392-022-02129-5","volume":"112","author":"C Schwab","year":"2023","unstructured":"Schwab C, Domke LM, Hartmann L, Stenzinger A, Longerich T, Schirmacher P. Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination. Clin Res Cardiol. 2023;112:431\u201340. https:\/\/doi.org\/10.1007\/s00392-022-02129-5. (Epub 2022 Nov 27. PMID: 36436002; PMCID: PMC9702955).","journal-title":"Clin Res Cardiol"},{"key":"2439_CR3","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782\u201393. https:\/\/doi.org\/10.1001\/jama.2020.12839. (PMID: 32648899).","journal-title":"JAMA"},{"key":"2439_CR4","doi-asserted-by":"publisher","first-page":"E311","DOI":"10.15167\/2421-4248\/jpmh2021.62.2.1627","volume":"62","author":"Y Alimohamadi","year":"2021","unstructured":"Alimohamadi Y, Tola HH, Abbasi-Ghahramanloo A, Janani M, Sepandi M. Case fatality rate of COVID-19: a systematic review and meta-analysis. J Prev Med Hyg. 2021;62:E311\u201320. https:\/\/doi.org\/10.15167\/2421-4248\/jpmh2021.62.2.1627.","journal-title":"J Prev Med Hyg"},{"key":"2439_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2471\/BLT.20.265892","volume":"99","author":"JPA Ioannidis","year":"2021","unstructured":"Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ. 2021;99:19-33F. https:\/\/doi.org\/10.2471\/BLT.20.265892. (Epub 2020 Oct 14. PMID: 33716331; PMCID: PMC7947934).","journal-title":"Bull World Health Organ"},{"key":"2439_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","volume":"69","author":"S Garg","year":"2020","unstructured":"Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019\u2014COVID-NET, 14 States, March 1\u201330, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:458\u201364. https:\/\/doi.org\/10.15585\/mmwr.mm6915e3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2439_CR7","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3390\/v15081764.PMID:37632107;PMCID:PMC10457914","volume":"15","author":"G Morgan","year":"2023","unstructured":"Morgan G, Casalino S, Chowdhary S, Frangione E, Fung CYJ, Haller S, Lapadula E, Scott M, Wolday D, Young J, Arnoldo S, Aujla N, Bearss E, Binnie A, Bombard Y, Borgundvaag B, Briollais L, Dagher M, Devine L, Faghfoury H, Friedman SM, Gingras AC, Goneau LW, Khan Z, Mazzulli T, McLeod SL, Nomigolzar R, Noor A, Pugh TJ, Richardson D, Satnam Singh HK, Simpson J, Stern S, Strug L, Taher A, Lerner-Ellis J, Taher J. Characterizing risk factors for hospitalization and clinical characteristics in a cohort of COVID-19 patients enrolled in the GENCOV study. Viruses. 2023;15:1764. https:\/\/doi.org\/10.3390\/v15081764.PMID:37632107;PMCID:PMC10457914.","journal-title":"Viruses"},{"key":"2439_CR8","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22:1293\u2013302. https:\/\/doi.org\/10.1016\/S1473-3099(22)00320-6. (Epub 2022 Jun 23. Erratum in: Lancet Infect Dis. 2023 Oct;23(10):e400. PMID: 35753318; PMCID: PMC9225255).","journal-title":"Lancet Infect Dis"},{"key":"2439_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.807","volume":"11","author":"F Yasmin","year":"2023","unstructured":"Yasmin F, Najeeb H, Naeem U, Moeed A, Atif AR, Asghar MS, Nimri N, Saleem M, Bandyopadhyay D, Krittanawong C, Fadelallah Eljack MM, Tahir MJ, Waqar F. Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia. Immun Inflamm Dis. 2023;11: e807. https:\/\/doi.org\/10.1002\/iid3.807. (PMID:36988252;PMCID:PMC10022421).","journal-title":"Immun Inflamm Dis"},{"key":"2439_CR10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34309","volume":"15","author":"M Ghoweba","year":"2023","unstructured":"Ghoweba M, Sabayon MD. Syncope with sinus arrest following a single dose of a COVID-19 vaccine. Cureus. 2023;15: e34309. https:\/\/doi.org\/10.7759\/cureus.34309. (PMID:36860236;PMCID:PMC9970110).","journal-title":"Cureus"},{"key":"2439_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.21037\/atm-22-4164","volume":"11","author":"A Ojo","year":"2023","unstructured":"Ojo A, Goldenberg I, Kutyifa V, Aktas MK, Rosero S, Ayinde H, Huang DT. Recurrent ventricular tachycardia in a patient with COVID-19 vaccine-associated myocarditis: a case report. Ann Transl Med. 2023;11:267. https:\/\/doi.org\/10.21037\/atm-22-4164. (Epub 2023 Feb 20. PMID: 37082660; PMCID: PMC10113094).","journal-title":"Ann Transl Med"},{"key":"2439_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18716","volume":"9","author":"M Altermanini","year":"2023","unstructured":"Altermanini M, Habib MB, Alkhiyami D, Ali K, Abdelghani MS, Hamamyh T, Elyas A, Elhassan M. Syncope following Pfizer BioNTech (bnt162b2) vaccination unmasking Brugada syndrome. Heliyon. 2023;9: e18716. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18716. (PMID:37576199;PMCID:PMC10415666).","journal-title":"Heliyon"},{"key":"2439_CR13","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, Hern\u00e1n MA, Lipsitch M, Kohane I, Netzer D, Reis BY, Balicer RD. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Na:onwide Se\u00c9ng. N Engl J Med. 2021;385:1078\u201390. https:\/\/doi.org\/10.1056\/NEJMoa2110475. (Epub 2021 Aug 25. PMID: 34432976; PMCID: PMC8427535).","journal-title":"N Engl J Med"},{"key":"2439_CR14","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.3390\/vaccines10101651","volume":"10","author":"M M\u00f6rz","year":"2022","unstructured":"M\u00f6rz M. A case report: Mul:focal Necro:zing Encephali:s and Myocardi:s aPer BNT162b2 mRNA Vaccina:on against COVID-19. Vaccines (Basel). 2022;10:1651. https:\/\/doi.org\/10.3390\/vaccines10101651. (PMID: 36298516; PMCID: PMC9611676).","journal-title":"Vaccines (Basel)"},{"key":"2439_CR15","unstructured":"Sicherheitsbericht \/ Safety Report of the Paul-Ehrlich-Institut (04.05.2022). https:\/\/www.pei.de\/SharedDocs\/Downloads\/DE\/newsroom\/dossiers\/sicherheitsberichte\/sicherheitsbericht-27-12-20-bis-31-03-22.pdf?__blob=publicationFile&v=5. Accessed: 18 Apr 2024"},{"key":"2439_CR16","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/vaccines11101621","volume":"11","author":"M Salsone","year":"2023","unstructured":"Salsone M, Signorelli C, Oldani A, Alber VF, Castronovo V, Mazzitelli S, Minerva M, Ferini-Strambi L. NEURO-COVAX: an Italian population-based study of neurological complica:onsaPer COVID-19 vaccina:ons. Vaccines (Basel). 2023;11:1621. https:\/\/doi.org\/10.3390\/vaccines11101621. (PMID: 37897023; PMCID: PMC10610846).","journal-title":"Vaccines (Basel)"},{"key":"2439_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/jdv.17744","volume":"36","author":"T Gambichler","year":"2022","unstructured":"Gambichler T, Boms S, Susok L, Dickel H, Finis C, Abu Rached N, Barras M, St\u00fccker M, Kasakovski D. Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol. 2022;36:172\u201380. https:\/\/doi.org\/10.1111\/jdv.17744. (Epub 2021 Nov 2. PMID: 34661927; PMCID: PMC8656409).","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2439_CR18","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/jamadermatol.2021.2114","volume":"157","author":"LB Robinson","year":"2021","unstructured":"Robinson LB, Fu X, Hashimoto D, et al. Incidence of cutaneous reactions after messenger RNA COVID-19 vaccines. JAMA Dermatol. 2021;157:1000\u20132. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2114.","journal-title":"JAMA Dermatol"},{"key":"2439_CR19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/09273948.2022.2055578","volume":"30","author":"A Sar\u0131g\u00fcl Sezen\u00f6z","year":"2022","unstructured":"Sar\u0131g\u00fcl Sezen\u00f6z A, G\u00fcng\u00f6r SG, Kibaro\u011flu S. A case of transient visual field defect following administration of Pfizer-BioNTech COVID-19 vaccine. Ocul Immunol Inflamm. 2022;30:1255\u20139. https:\/\/doi.org\/10.1080\/09273948.2022.2055578. (Epub 2022 Apr 11 PMID: 35404749).","journal-title":"Ocul Immunol Inflamm"},{"key":"2439_CR20","doi-asserted-by":"publisher","first-page":"101212","DOI":"10.1016\/j.ajoc.2021.101212","volume":"24","author":"C Jumroendararasame","year":"2021","unstructured":"Jumroendararasame C, Panyakorn S, Othong R, Jumroendararasame A, Srimanan W, Tipparut K. Transient visual field loss after COVID-19 vaccination: experienced by ophthalmologist, case report. Am J Ophthalmol Case Rep. 2021;24:101212. https:\/\/doi.org\/10.1016\/j.ajoc.2021.101212. (Epub 2021 Sep 23. PMID: 34580649; PMCID: PMC8457908).","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2439_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.32433","volume":"14","author":"J Finsterer","year":"2022","unstructured":"Finsterer J. A case report: long post-COVID vaccination syndrome during the eleven months after the third moderna dose. Cureus. 2022;14: e32433. https:\/\/doi.org\/10.7759\/cureus.32433. (PMID:36644105;PMCID:PMC9833629).","journal-title":"Cureus"},{"key":"2439_CR22","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","volume":"6","author":"X Hou","year":"2021","unstructured":"Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6:1078\u201394. https:\/\/doi.org\/10.1038\/s41578-021-00358-0. (Epub 2021 Aug 10. PMID: 34394960; PMCID: PMC8353930).","journal-title":"Nat Rev Mater"},{"key":"2439_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.phrs.2015.08.003","volume":"100","author":"LE Guimar\u00e3es","year":"2015","unstructured":"Guimar\u00e3es LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190\u2013209. https:\/\/doi.org\/10.1016\/j.phrs.2015.08.003. (Epub 2015 Aug 12. PMID: 26275795; PMCID: PMC7129276).","journal-title":"Pharmacol Res"},{"key":"2439_CR24","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.7326\/M21-1976","volume":"174","author":"DT Arnold","year":"2021","unstructured":"Arnold DT, Milne A, Samms E, Stadon L, Maskell NA, Hamilton FW. Symptoms after COVID-19 vaccination in patients with persistent symptoms after acute infection: a case series. Ann Intern Med. 2021;174:1334\u20136. https:\/\/doi.org\/10.7326\/M21-1976. (Epub 2021 May 25. PMID: 34029484; PMCID: PMC8252827).","journal-title":"Ann Intern Med"},{"key":"2439_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/vaccines10050652","volume":"10","author":"WD Strain","year":"2022","unstructured":"Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. The impact of COVID vaccination on symptoms of long COVID: an international survey of people with lived experience of long COVID. Vaccines (Basel). 2022;10:652. https:\/\/doi.org\/10.3390\/vaccines10050652. (PMID:35632408;PMCID:PMC9146071).","journal-title":"Vaccines (Basel)"},{"key":"2439_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069676","volume":"18","author":"D Ayoubkhani","year":"2022","unstructured":"Ayoubkhani D, Bermingham C, Pouwels KB, Glickman M, Nafilyan V, Zaccardi F, Khunti K, Alwan NA, Walker AS. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ. 2022;18: e069676. https:\/\/doi.org\/10.1136\/bmj-2021-069676. (PMID:35584816;PMCID:PMC9115603).","journal-title":"BMJ"},{"key":"2439_CR27","unstructured":"Gaber, T.A.-Z.K. et al.; \u2018Are mRNA Covid 19 vaccines safe in Long Covid patients? A Health Care Workers perspective\u2019; British Journal of Medical Practitioners 2021: https:\/\/www.bjmp.org\/files\/2021-14-1\/bjmp-2021-14-1-a008.pdf. Accessed 16 Oct 2024"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02439-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-024-02439-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-024-02439-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T19:08:59Z","timestamp":1743880139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-024-02439-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2439"],"URL":"https:\/\/doi.org\/10.1007\/s15010-024-02439-y","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.W. has nothing to disclose. G.S. received funding from Gilead Sciences and speaker fees from ViiV Healthcare, Bristol Meyer Squibb, MSD and Hormosan for participation in Advisory Boards, Data Safety and Montitoring Boards and for preparation of educational materials and lecturing fees. M.J.G.T.V. has received research grants from 3\u00a0M, Astellas Pharma, Biontech, DaVolterra, Evonik, Gilead Sciences, Glycom, Immunic, MaaT Pharma, Merck\/MSD, Organobalance, Seres Therapeutics, Takeda Pharmaceutical and speaker fees and\/or consulting fees from Astellas Pharma, Basilea, Bio-M\u00e9rieux, DaVolterra, Farmak International Holding GmbH, Ferring, Gilead Sciences, Immunic AG, MaaT Pharma, Merck\/MSD, Pfizer, Roche, Organobalance, SocraTec R&D GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The patient gave written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"We received consent for submission and publication of the case report to the journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}